Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. - Wikidata - awgldk - TriplyDB

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.

http://www.wikidata.org/entity/Q31120426

about

Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion Retinal vein occlusion: pathophysiology and treatment options The related transcriptional enhancer factor-1 isoform, TEAD4(216), can repress vascular endothelial growth factor expression in mammalian cells Anterior chamber depth and angle-closure glaucoma after central retinal vein occlusion RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.Vitrectomy may prevent the occurrence of diabetic macular oedema.Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.Neovascular glaucoma Transient inhibition of transforming growth factor-beta1 in human diabetic CD34+ cells enhances vascular reparative functions.Role of vascular endothelial growth factor in the breakdown of the blood-aqueous barrier after retinal laser photocoagulation in pigmented rabbits.Antiangiogenic therapy for ischemic retinopathies.Lens subluxation after plasmin and SF6 injections in rabbit eyes.Endoglin (CD105) expression in the development of haemorrhoids.Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study).A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.Targeted photocoagulation of peripheral ischemia to treat rebound edema.Clinical and histological characteristics of canine ocular gliovascular syndrome.Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.Vascular endothelial growth factor biology: clinical implications for ocular treatments Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials.Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.Management of retinal vascular diseases: a patient-centric approach.Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study prot Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy.Pegaptanib sodium for ocular vascular disease.Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion.Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion.Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review

P2860

Q24194332-5928A87D-26DA-48D9-8FC6-6E8B14E5A1D0 Q24194783-D3692D23-53EA-4A17-A226-DBA9D89470E2 Q24201821-B77711FD-4557-43D4-BEB9-AB50F6EA78CC Q24234625-65396A35-DC5F-44B7-B4F7-306B5A59A710 Q24234750-906B3F77-E817-4646-B9E5-2A1BE545DD67 Q24242868-79F54036-7F4B-4D9D-AF5D-A75F50A46834 Q24596993-9BF72CA6-01FD-4B44-A776-CFB5D54D401E Q28728051-78CFC579-AA68-4080-8831-863575EA3D20 Q30382208-352BCC22-5CAD-4953-8114-E44B40CC06E4 Q30490830-AF541934-AF54-4164-80ED-4F7571D9D192 Q31163540-A4A1B0A0-3210-4F95-BF40-2F6A905D43B6 Q33335166-FD0801CC-1714-4E53-A6AA-09D580580C1B Q33457562-3853F1E9-A610-473F-8B02-D10E6CA7B386 Q33737235-4C658034-37A8-4D4A-A3EE-C74FC3114365 Q33855412-43233AAC-4CA1-4C02-9DE5-B631D697290B Q34024355-74D88C61-4B0C-4E48-92BD-A73F4105C68A Q34051527-8EB030CA-F0FA-4AE8-A85B-B81FE67A154D Q34295974-C550423C-7AD0-4B84-B988-97E7F117837E Q34514583-99604772-F551-426B-ADDB-806A179DECA9 Q34545010-A634959D-EBB0-4981-9225-CAE51FB8732B Q34826956-110EC160-55F4-4EC1-9B82-32783B86A97A Q35068919-2389978B-4239-4FF8-9702-3B7F97C60EE0 Q35077598-9D6700F9-D921-46FB-A4F8-AED9D0FCADE0 Q35089799-BB2D0302-A677-434B-BCC4-28BF26DD9E40 Q35105168-ABB880F1-28EE-48A8-898A-5B9663D5BCA5 Q35235652-DE2D74DC-78F1-4CCA-810B-D5D71ECA08CA Q35238074-AE71A161-5365-446E-8CB9-C619BF00F68C Q35762769-3333142E-AB9C-4F69-A111-7FD3C97BBE34 Q35769968-9560E8F0-C1B5-4B12-BD2C-43CFE5F6F49A Q35872579-492A092F-4663-4A13-BA6C-007A0A05815F Q35909406-B9F59150-B77C-4BC7-80FC-DD90C35BB78C Q36224527-72FC1B28-2111-4772-A54D-0837E9CEE718 Q36311337-5BD33DCB-2908-4289-A407-9E7FA8AEFB8A Q36667368-C4C53CF9-852F-4931-8530-77CEE07B7DBF Q36977426-D74C866F-2E29-4359-BFA4-C8E3F8A218DE Q37170006-5D2EAEAF-C980-4937-B119-5766F4F89F95 Q37236106-C4BE1DE8-AF92-4403-A79F-6FB1496BDAEE Q37418304-A4346E33-475E-4937-AA6B-1525245E4DCF Q37468754-1922E70A-2E05-47CC-8BE9-9BBD66B4A590 Q38364703-1D030200-A2CB-4FE1-9397-DEE197EF56CF

P2860

Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.

http://www.wikidata.org/entity/Q31120426

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Correlation of increased vascu ...... chemic central vein occlusion.

@ast

Correlation of increased vascu ...... chemic central vein occlusion.

@en

type

label

Correlation of increased vascu ...... chemic central vein occlusion.

@ast

Correlation of increased vascu ...... chemic central vein occlusion.

@en

prefLabel

Correlation of increased vascu ...... chemic central vein occlusion.

@ast

Correlation of increased vascu ...... chemic central vein occlusion.

@en

P1433

Q31120426-A329E70F-7CF5-4B60-9951-59FC334F3899

P1476

Q31120426-D9ABB704-F47A-4962-B2FB-BBAF33A42619

P2093

Q31120426-0FEB1765-3AC0-46D7-BFCC-C5BF178126B3

Q31120426-1D112430-BC38-4834-93EA-F4F8B56AFBA8

Q31120426-31A5E578-6DE5-4ED8-B767-A7889E991B54

Q31120426-37051BE3-2D72-401F-B533-DCC095C7A56F

Q31120426-40B04ADE-4E3B-493B-802D-95496C94BCE5

Q31120426-4CE130C7-8B25-4335-BB7B-9F5D007DADC1

Q31120426-5EE08362-BC7A-46BE-A064-9F23A3A25549

Q31120426-9D10DF53-CD33-48D0-946A-9C0C7605A082

P304

Q31120426-79A047FA-C8FA-4E5B-B59E-991BC93A152A

P31

Q31120426-613A60EB-C8D7-4185-8B21-982D1EA927CE

P356

Q31120426-86A7BEA4-9E1C-48AC-9A8E-0DCECE262ABE

P407

Q31120426-7C7816E9-2373-462F-BDB2-62C45EE6536C

P433

Q31120426-DA6E3534-7959-4BF0-A101-9FE920B57A58

P478

Q31120426-8F35759B-7BB5-4975-87DC-28C22AF6CB41

P577

Q31120426-2BC043DA-F47A-4670-944E-A89C69AF3B59

P698

Q31120426-12ABFADB-01B7-4184-8287-2103CC498A27

P921

Q31120426-CA5DCEA5-8711-4700-B8B9-B99C589E0F70

Q31120426-EEB6D63F-1DAF-467A-A480-6839CC8FDA14

P356

ARCHOPHT.120.12.1644

P1433

JAMA Ophthalmology

P1476

Correlation of increased vascu ...... chemic central vein occlusion.

@en

P2093

G Brian Wisdom

http://www.w3.org/2001/XMLSchema#string

George J Allen

http://www.w3.org/2001/XMLSchema#string

Ian A Cree

http://www.w3.org/2001/XMLSchema#string

Ian Zachary

http://www.w3.org/2001/XMLSchema#string

John F Martin

http://www.w3.org/2001/XMLSchema#string

Philip G Hykin

http://www.w3.org/2001/XMLSchema#string

Shelley R Boyd

http://www.w3.org/2001/XMLSchema#string

Usha Chakravarthy

http://www.w3.org/2001/XMLSchema#string

P304

1644-1650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHT.120.12.1644

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12470137

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization